Q3 2025 Trevi Therapeutics Inc Earnings Call Transcript
Key Points
- Trevi Therapeutics Inc (TRVI) reported positive data readouts from both the coral trial for chronic cough in IPF patients and the river trial for RCC patients.
- The company successfully raised approximately $115 million in June, providing a cash runway into 2028.
- Recent phase one studies showed no clinically meaningful changes in pharmacokinetics when nalbuphine was co-administered with standard IPF treatments.
- An external safety review committee found no safety signals in the respiratory function study, allowing the completion of enrollment.
- Trevi Therapeutics Inc (TRVI) is financially strong, with cash and investments totaling approximately $195 million as of September 30, 2025.
- Trevi Therapeutics Inc (TRVI) reported a net loss of $11.8 million for the third quarter of 2025.
- R&D expenses decreased due to reduced clinical trial work, but G&A expenses increased due to higher professional fees and personnel costs.
- The company anticipates needing to conduct additional drug-drug interaction studies based on the mechanism of drug metabolism.
- The FDA requested a specific respiratory safety study despite existing data from 200 IPF patients, indicating regulatory hurdles.
- The company faces the challenge of aligning with the FDA on the phase 3 program design and other parameters for chronic cough in IPF patients.
Than everyone. Good afternoon and welcome to the Trevi Therapeutics 3rd quarter 2025 earnings conference call. (Operator instructions).
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of the company's most recent quarterly report on Form 10k which the company filed with the SEC this afternoon. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so if.
Its views change. I would now like to turn the conference over to Jennifer Good, Trevi's President and CEO. Please go ahead.
Good afternoon and thank you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
